Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Objective: To determine if atomoxetine 40 mg bid (bis in die) in patients ≥18 years old with
recurrent vasovagal syncope will better prevent syncope during tilt testing than placebo.